Peripheral blood and bone marrow samples from patients less
informed consent was obtained. Diagnoses were made by standard clinical and haematologic criteria. Only samples in which the blast cell count was greater than 70% were used Introduction in this study. Leukaemic blasts were separated by centrifugation over Ficoll Paque (Pharmacia, Uppsala, Sweden) from The Wilms' tumour suppressor gene, WT1, encodes a zincthe peripheral blood or bone marrow and stored at −70°C. finger protein that is postulated to function as a bifunctional Thirty-three cases of ALL (one non-B non-T-ALL, 11 T-ALL, 16 transcription factor in vivo.
1 WT1 gene targeting in mouse pre-B ALL, one Ph +ve ALL and four ALL of unknown embryos has shown that WT1 plays a critical role in early immunophenotype) and 15 cases of AML were examined in nephrogenesis and in the development of the gonads.
2 WT1 the study. (All, except one relapse T-ALL, were presentation is expressed predominantly in tissues of mesodermal origin cases.) Characteristics of the AML samples used in the study including the kidney, gonads, mesothelial lining of the gut, are described in Table 1 . Genomic DNA was extracted using heart and lung. 1, 3 It is also expressed in the spleen and in a the QIAamp Tissue Kit (Qiagen, Chatsworth, USA). SSCP was subset of immature cells in the bone marrow. Mutations in the performed at 15°C on 7% polyacrylamide gels containing 5% WT1 gene have been identified in Wilms' tumours, in mesoglycerol run in 1XTBE at 40 W. DNA (200 ng) was subjected thelioma and in the acute myeloid leukaemia of a patient with to PCR amplification incorporating ␣ 32 P-dCTP in the reaction a previous history of Wilms' tumour. 4, 5 More recently, WT1 using the primers and conditions described in Table 2 . Primer point mutations have been identified in sporadic AML in adult pairs E2, E3, E4, E5, E6, E9 and E10 were taken from Baird et patients with particularly aggressive disease.
6 Recent studies al. 13 Owing to the large size of exon 1, three separate PCR have suggested that WT1 plays a role in definitive haematopofragments spanning the region from 39 bp upstream of the iesis with high levels of expression seen in murine embryonic translation initiation codon and extending into the downliver at 12 d.p.c and in normal CD34
+ bone marrow stem stream intron, were analysed by SSCP. WT1 expression was cells. 7 The gene is expressed in acute phase malignant haemaexamined by RT-PCR on cDNA reverse transcribed from 1 g topoietic cells of both myeloid and lymphoid origin and is of total RNA. RNA was extracted by the method of Chomczyndown-regulated during differentiation.
8-11 WT1 is more freski and Sacchi 14 and reverse transcribed using 200 U of quently expressed in myeloid compared with lymphoid leukaemias and is less frequently expressed in non-Hodgkin's lymphoma.
12 WT1 is only weakly expressed in normal mature blood cells and in chronic phase leukaemias. Patients with leukaemias exhibiting high levels of WT1 gene expression have been shown to have a poor response to treatment and consequently worse prognosis. 12 Current evidence suggests therefore that both elevated WT1 expression and WT1 gene mutations may mark leukaemias with poor prognosis.
We were interested in establishing whether WT1 gene -3F  5ЈCGAGGAGCAGTGCCTGAGC3Ј  56  1  249  WTE1-3R  5ЈAGCGGAGAGTCCCTGGCG3Ј   E2  5ЈEX2  5ЈACCGCTGACACTGTGCTTCTCTCCG3Ј  58  2  215  3ЈEX2  5ЈAGAGGAGGATAGCACGGAAG3Ј   E3  5ЈEX3  5ЈGGCAGCACTCGCTCAGCTGTCTTCG3Ј  65  3  180  3ЈEX3  5ЈGGTCCCAAGGACCCAGACGCAGAGC3Ј   E4  5ЈEX4  5ЈGTGGTTATGTGTTCTAACTCTAGAT3Ј  58  4  158  3ЈEX4  5ЈATAAGTTACTGTGGAAAGGCAATGG3Ј   E5  5ЈEX5  5ЈGCTCCATTCCCCACTCCCCACCTCT3Ј  65  5  120  3ЈEX5  5ЈTTGCTTTGCCATCTCCGCATTGTCC3Ј   E6  5ЈEX6  5ЈCACTGACCCTTTTTCCCTTC3Ј  55  6  189  3ЈEX6  5ЈGGCCGGTAAGTAGGAAGAGGC3Ј   E7  WT1-7F  5ЈATGTGCTTAAAGCCTCCCTTCC3Ј  61  7  225  WT1-7R  5ЈGTTTGCCCAAGACTGGACAGCG3Ј   E8  953  5ЈGCCTTTAATGAGATCCCCTTTTCC3Ј  59  8  191  3ЈEX8  5ЈAGGGAACACAGCTGCCAGCAATGAG3Ј   E9  5ЈEX9  5ЈTAGGGCCGAGGCTAGACCTTCTCTG3Ј  55  9  204  3ЈEX9  5ЈATCCCTCTCATCACAATTTCATTCC3Ј   E10  5ЈEX10  5ЈGCAAGTGTCTCTGACTGGCAATTGT3Ј  55  10  190  3ЈEX10  5ЈTGCCTGGGACACTGAACGGTCCCCG3Ј MMLV reverse transcriptase in 1 × RT buffer (Promega) conResults and discussion taining 6.5 U RNAsin, 1 mm dNTPs and 1 nmole of random hexamers at 37°C for 60 min. WT1 cDNA was amplified using SSCP analysis of 33 ALL and 15 AML patient DNA samples using the PCR strategy outlined in Table 2 did not result in primers WTE6 (5Ј CCACAGCACAGGGTACGAGA 3Ј) and WS12 (5Ј CCTTTGGTGT-CTTTTGAGCTGGTCTGAAC 3Ј) at any band shifts that could be identified as being associated with tumorigenic point mutations in the WT1 gene in these 60°C for 1 min, 72°C for 1 min 30 s, and 94°C for 1 min for 35 cycles. The 328 bp products were run out on 1% agarose, samples. Where abnormal bands were detected, SSCP was repeated to confirm any shifts and samples were sequenced blotted onto nylon membrane and probed with the same 32 Plabelled PCR product amplified from WT33 cDNA.
in both forward and reverse directions by direct sequencing using an ABI 370A automated sequencing system. SSCP run eage differentiation. Recent work in our laboratory, using WT1 antisense oligonucleotides to abrogate WT1 protein lengths and conditions were varied to give maximal separation of double-and single-stranded DNA. SSCP analysis of expression in leukaemia cell lines, has suggested that wildtype WT1 may play a direct role in the proliferation of some exon 7 produced three distinct banding patterns (see Figure  1) . Subsequent sequencing of these samples revealed the presmyeloid leukaemias and that it may also play a role in maintaining leukaemia cell viability, possibly by suppressing ence of a previously described polymorphism resulting in an A to G transition at position 9 from the start of exon 7. Heteroapoptosis. 16 However, this response was dependent on the cell line tested with not all cell lines exhibiting reduced prozygous and homozygous samples were readily distinguishable by both SSCP analysis and direct sequencing. The frequency liferation in association with WT1 antisense treatment. The role that WT1 plays in the haematopoietic process is therefore of the alternate allele (21.5%) was equivalent to that reported in the normal population. WT1 expression was examined by complex. Future work using animal models overexpressing wild-type and mutant forms of WT1 may answer some of the RT-PCR in a subset of the leukaemia panel. In all of the samples examined (13 AMLs and 12 ALLs) WT1 expression questions concerning the role of this gene in haematopoiesis. could be detected. The levels of expression were in general higher in the AML samples as compared with the ALLs. However, an accurate quantitation and comparison of WT1 Acknowledgements expression levels by Northern blotting in these patients could not be done due to insufficient amounts of RNA being availThis work was supported by the Queensland Cancer Fund and able for this purpose. Figure 2 shows the result of RT-PCR the Royal Children's Hospital Foundation (Brisbane). We are detecting a 328 bp product in 12 AML samples that were indebted to the nursing and medical staff at the Royal Chilexamined in this study. WT1 is therefore expressed at detectdren's Hospital, Brisbane, Australia, for the collection of able levels in both leukaemias of childhood and adulthood.
patient material and to Dr George Kannourakis at the Royal This is the first study in which sporadic childhood leuChildren's Hospital in Melbourne for the provision of AML kaemias have been examined for WT1 point mutations across samples. the entire coding region of the gene, however, WT1 mutations appear to be an infrequent event in childhood leukaemia as in all 48 cases examined, a structurally normal gene was References present. This is in contrast to the findings in adult leukaemias where 15% of AML cases were found to carry inactivating point mutations in the WT1 gene. Whereas p53 shows increased expression in association with
